Pilot runs in Europe and South America show breakthrough efficiency in monoclonal antibody production with unprecedented cost savings and scalability using Stämm's bubble-free continuous laminar flow ...
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...